Member Info for Laura2022

The first order is valued at c. £160,000, with total annual orders from the customer potentially worth up c.£650,000 per annum going forward, subject to the contract proceeding as expected.

Touching on 100% up now on these but expecting more

Thats genuinely too funny

Omg

I assume a green box was not even aware IMM were at this conference??

Dear me, what sad people

2009!!

17yrs..mostly whining on IMM

Live your best life ♡

Please research and stick to FARN

Just accept that those who need/are filtered are not worthy of any air time

They are clearly unwell and have no other joy

Just filter

It's bliss

After close

Seems to have cleared things ?

GG

Slow day on AIM across board + small overhang to clear

Weill bounce quickly

They needed funds during May 2026

Lets see

Anyone any thoughts?

P140 partnering discussions

As reiterated in recent announcements, P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value‑enhancing licensing deal in 2026.

The structure of the Lanstead subscription provides a mechanism through which the Company may potentially benefit from future share price performance, with the 8p Benchmark Price acting as the reference point for returns under the Sharing Arrangement. The Board therefore believes that continued operational progress and news flow relating

P140 and Kapiglucagon, have the potential to support value creation over the period of the agreement.

Importantly, the successful fundraising extends the Company's cash runway to at least H2 2028*. This strong financial leverage enhances our ability to negotiate a P140 licensing agreement from a position of strength, while also providing the flexibility to accelerate the Kapiglucagon program and selectively invest in earlier-stage pipeline opportunities.

 

With the progress already underway, the Board believes 2026 will be a year of delivery, momentum, and success for ImmuPharma and its shareholders.

Increasing, would expect sone updates /plans /contracts soon

4.7p paid now

Remember-

structure of the Lanstead subscription provides a mechanism through which the Company may potentially benefit from future share price performance, with the 8p Benchmark Price acting as the reference point for returns under the Sharing Arrangement. The Board therefore believes that continued operational progress and news flow relating

P140 and Kapiglucagon, have the potential to support value creation over the period of the agreement.

Importantly, the successful fundraising extends the Company's cash runway to at least H2 2028

Reported yesterday from 1st May

0.13692

36,500,000

Unknown£ 49.98k

Oil revenues is key

The oil revenues will be double in 2026 as oil now $100+ rather than $50 for their 2025 revenues :

Absolutely crashed on the chart indicators, a confident RNS from CEO in results about objectives and $2.5mln due versus a £4mln market cap

Strategic Context

The extended production test at Sagebrush-1 represents a key step in Quantum's strategy to unlock the value of its helium portfolio.

The Company holds over 1 Bcf of 2U prospective recoverable helium resources across Sagebrush and Coyote Wash, representing one of the largest independently assessed helium portfolios among London-listed companies.

Rev

Youre clearly a new old ID

I'll filter

Best wishes

Then sell and move on after whinging on here for years ?

There's 100s of other investments